Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus ORAPRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus ORAPRED.
CORTIFOAM vs ORAPRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune responses, and adrenal function.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
5-60 mg orally once daily or divided as 5-15 mg every 4-12 hours; adjust based on response and condition.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
4-5 hours (terminal); prolonged in renal impairment (up to 12+ hours in anuria) and hepatic dysfunction; clinical context: dosing interval adjustment in severe renal failure
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal: approximately 60-80% as unchanged drug and conjugated metabolites; biliary/fecal: minor (5-10%)
Category C
Category C
Corticosteroid
Corticosteroid